BioCentury | May 7, 2007
Clinical News

ST-603: Phase III started

...Sirion began a Phase III trial of topical ST-603. Laboratorios Sophia granted Sirion rights to develop and...
...the U.S. last year (see BioCentury, July 31, 2006). Sirion Therapeutics Inc. , Tampa, Fla. Laboratorios Sophia S.A. de C.V....
BioCentury | Apr 11, 2007
Financial News

Sirion raises $45 million

...containing difluprednate to treat inflammation following ocular surgery. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...
BioCentury | Sep 25, 2006
Company News

Sirion, Tenby Pharma Inc. deal

...inflammation in the first half of next year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia S.A. de C.V....
BioCentury | Sep 19, 2006
Financial News

Sirion reverse-merges, raises $25M

...inflammation in the first half of next year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...
BioCentury | Aug 21, 2006
Company News

Sirion, Sytera Inc. deal

...to treat age-related macular degeneration (AMD) this year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia S.A. de C.V....
BioCentury | Aug 17, 2006
Company News

Sirion, Sytera merge

...to treat age-related macular degeneration (AMD) this year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...
BioCentury | Jul 31, 2006
Company News

Sirion, Laboratorios Sophia deal

...first half of 2007. Financial terms were not disclosed. Sirion Therapeutics Inc. , Tampa, Fla. Laboratorios Sophia S.A. de C.V....
BioCentury | Mar 6, 2000
Company News

Clear Solutions Biotech Inc., Laboratorios Sophia deal

...sustained delivery of genes to the eye. Clear Solutions Biotech Inc. , Stony Brook, N.Y. Laboratorios Sophia S.A. de C.V....
Items per page:
1 - 8 of 8
BioCentury | May 7, 2007
Clinical News

ST-603: Phase III started

...Sirion began a Phase III trial of topical ST-603. Laboratorios Sophia granted Sirion rights to develop and...
...the U.S. last year (see BioCentury, July 31, 2006). Sirion Therapeutics Inc. , Tampa, Fla. Laboratorios Sophia S.A. de C.V....
BioCentury | Apr 11, 2007
Financial News

Sirion raises $45 million

...containing difluprednate to treat inflammation following ocular surgery. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...
BioCentury | Sep 25, 2006
Company News

Sirion, Tenby Pharma Inc. deal

...inflammation in the first half of next year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia S.A. de C.V....
BioCentury | Sep 19, 2006
Financial News

Sirion reverse-merges, raises $25M

...inflammation in the first half of next year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...
BioCentury | Aug 21, 2006
Company News

Sirion, Sytera Inc. deal

...to treat age-related macular degeneration (AMD) this year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia S.A. de C.V....
BioCentury | Aug 17, 2006
Company News

Sirion, Sytera merge

...to treat age-related macular degeneration (AMD) this year. Sirion has U.S. rights to ST-603 from Laboratorios Sophia...
BioCentury | Jul 31, 2006
Company News

Sirion, Laboratorios Sophia deal

...first half of 2007. Financial terms were not disclosed. Sirion Therapeutics Inc. , Tampa, Fla. Laboratorios Sophia S.A. de C.V....
BioCentury | Mar 6, 2000
Company News

Clear Solutions Biotech Inc., Laboratorios Sophia deal

...sustained delivery of genes to the eye. Clear Solutions Biotech Inc. , Stony Brook, N.Y. Laboratorios Sophia S.A. de C.V....
Items per page:
1 - 8 of 8